CoChat
Sign Up
Cited by 128Lipoproteins and Cardiovascular HealthPharmacogenetics and Drug MetabolismCholesterol and Lipid Metabolism

Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients.

Lins, R. L., Matthys, K. E., Verpooten, G. A., Peeters, P. C., Dratwa, M., Stolear, J.-C., Lameire, N. H.·2003·Nephrology Dialysis Transplantation
DOI 10.1093/ndt/gfg048
Open this paper in CoChat — free account

Abstract

BACKGROUND: Patients with chronic renal failure commonly suffer from a secondary form of complex dyslipidaemia, and may benefit from lipid-lowering treatment. Atorvastatin has been shown to reduce efficiently the levels of atherogenic lipoproteins also in patients with renal failure, but pharmacokinetic data in haemodialysis patients are lacking. METHODS: In this study, hypercholesterolaemic haemodialysis patients received 40 mg (n=12) or 80 mg (n=11) atorvastatin once daily, first as a single dose and then continuously for 2 weeks. Plasma levels of atorvastatin and its active and inactive metabolites were measured by LC/MS/MS, and pharmacokinetic parameters (C(max), t(max), AUC, t(1/2)) compared between single and multiple dosing, and between the different doses. RESULTS: The pharmacokinetic parameters of the parent drug atorvastatin acid were not significantly different after single and 2-week multiple dosing; they showed dose-proportionality between the 40 and 80 mg dose, and were comparable to findings in healthy volunteers. Dose-proportionality and absence of accumulation was also observed for the major active metabolite ortho-hydroxy-atorvastatin and the inactive metabolites atorvastatin lactone and ortho-hydroxy-atorvastatin lactone, but the levels of the active metabolite were relatively lower, and the inactive metabolites higher, compared with healthy volunteers. The para-hydroxy-metabolites constituted only a minor pathway in atorvastatin's metabolic elimination. Haemodialysis did not cause enhanced clearance of atorvastatin or its metabolites, the drug was well tolerated and there were no serious adverse events. CONCLUSION: While subtle differences may exist in the metabolic processing of atorvastatin in haemodialysis patients, active drug did not accumulate nor did it show enhanced elimination, and levels were comparable to those measured in healthy volunteers. Therefore there is no need to adapt atorvastatin dosage in this particular patient population.

Integrity signals

Registry

Crossref · 10.1093/ndt/gfg048

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Lins, R. L., Matthys, K. E., Verpooten, G. A., Peeters, P. C., Dratwa, M., Stolear, J.-C., & Lameire, N. H.
ORCID
Venue
Nephrology Dialysis Transplantation
Publisher
Oxford University Press (OUP)
Published
2003-05-01
Volume
18
Issue
5
Pages
967-976
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
DOI
10.1093/ndt/gfg048
OpenAlex
W2146427394
Cited by
128
References
39
Citations by year
2026: 7 · 2025: 1 · 2024: 9 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 5 · 2019: 8 · 2018: 3 · 2017: 3 · 2016: 6 · 2015: 9 · 2014: 4 · 2013: 10 · 2012: 7
FWCI
4.73
Type
journal article
Language
en
Open access
closed
Locations
  • Nephrology Dialysis Transplantation (publishedVersion)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
atorvastatin, pharmacokinetics, hemodialysis, hypercholesterolemia, chronic kidney disease, drug metabolites, dose proportionality, drug accumulation, lipid-lowering therapy, dose adjustment
MeSH terms
Atorvastatin, Adult, Aged, Anticholesteremic Agents, Drug Tolerance, Female, Half-Life, Renal Dialysis, Heptanoic Acids, Humans, Hypercholesterolemia, Kidney Failure, Chronic, Male, Middle Aged, Pyrroles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review